Physicians from The Johns Hopkins Scleroderma Center work closely with colleagues from around the nation.
The Johns Hopkins Scleroderma Center works collaboratively with faculty from the Johns Hopkins Division of Rheumatology, other members of Johns Hopkins University, and investigators and clinicians from other institutions:
- Michael Simons, M.D., Professor of Medicine and of Pharmacology & Toxicology, Dartmouth Medical School
- Maureen Mayes, M.D., M.P.H., Professor of Medicine, University of Texas Health Science Center at Houston
- John Varga, M.D., Gallagher Research Professor in Rheumatology, Northwestern University Feinberg School of Medicine
- Virginia D. Steen, M.D., Professor of Medicine, Georgetown University Medical Center
In addition, Johns Hopkins Scleroderma Center physicians and staff collaborate with private industry to develop novel treatments and new tools for studying scleroderma:
- Asahi Kasei Pharma Corporation, on a study of the vasodilating drug fasudil
- MediQuest Therapeutics, Inc., on study of a topical drug for Raynaud’s disease
- Novartis, on a study of its cancer drug Gleevec®